Home  ||| S:0 E:5 ||| RB
hospice  ||| S:5 E:13 ||| JJ
care  ||| S:13 E:18 ||| NN
for  ||| S:18 E:22 ||| IN
the  ||| S:22 E:26 ||| DT
patients  ||| S:26 E:35 ||| NNS
with  ||| S:35 E:40 ||| IN
gynecological  ||| S:40 E:54 ||| JJ
malignancies  ||| S:54 E:67 ||| NN
In  ||| S:67 E:70 ||| IN
order  ||| S:70 E:76 ||| NN
to  ||| S:76 E:79 ||| TO
clarify  ||| S:79 E:87 ||| VB
the  ||| S:87 E:91 ||| DT
clinical  ||| S:91 E:100 ||| JJ
characteristics  ||| S:100 E:116 ||| NNS
along  ||| S:116 E:122 ||| IN
with  ||| S:122 E:127 ||| IN
the  ||| S:127 E:131 ||| DT
practical  ||| S:131 E:141 ||| JJ
care  ||| S:141 E:146 ||| NN
of  ||| S:146 E:149 ||| IN
home  ||| S:149 E:154 ||| NN
hospice  ||| S:154 E:162 ||| NN
care  ||| S:162 E:167 ||| NN
for  ||| S:167 E:171 ||| IN
gynecological  ||| S:171 E:185 ||| JJ
cancer  ||| S:185 E:192 ||| NN
patients ||| S:192 E:200 ||| NNS
,  ||| S:200 E:202 ||| ,
we  ||| S:202 E:205 ||| PRP
analyzed  ||| S:205 E:214 ||| VBD
37  ||| S:214 E:217 ||| CD
terminally-ill  ||| S:217 E:232 ||| JJ
gynecological  ||| S:232 E:246 ||| JJ
cancer  ||| S:246 E:253 ||| NN
patients  ||| S:253 E:262 ||| NNS
who  ||| S:262 E:266 ||| WP
died  ||| S:266 E:271 ||| VBD
at  ||| S:271 E:274 ||| IN
home  ||| S:274 E:279 ||| NN
from  ||| S:279 E:284 ||| IN
July  ||| S:284 E:289 ||| NNP
1 ||| S:289 E:290 ||| CD
,  ||| S:290 E:292 ||| ,
2003  ||| S:292 E:297 ||| CD
through  ||| S:297 E:305 ||| IN
June  ||| S:305 E:310 ||| NNP
30 ||| S:310 E:312 ||| CD
,  ||| S:312 E:314 ||| ,
2010 ||| S:314 E:318 ||| CD
,  ||| S:318 E:320 ||| ,
and  ||| S:320 E:324 ||| CC
these  ||| S:324 E:330 ||| DT
patients  ||| S:330 E:339 ||| NNS
were  ||| S:339 E:344 ||| VBD
compared  ||| S:344 E:353 ||| VBN
with  ||| S:353 E:358 ||| IN
762  ||| S:358 E:362 ||| CD
non-gynecology  ||| S:362 E:377 ||| JJ
cancer  ||| S:377 E:384 ||| NN
patients ||| S:384 E:392 ||| NNS
.  ||| S:392 E:394 ||| .
The  ||| S:394 E:398 ||| DT
range  ||| S:398 E:404 ||| NN
of  ||| S:404 E:407 ||| IN
patients ||| S:407 E:415 ||| NNS
'  ||| S:415 E:417 ||| POS
ages  ||| S:417 E:422 ||| NNS
with  ||| S:422 E:427 ||| IN
gynecological  ||| S:427 E:441 ||| JJ
malignancies  ||| S:441 E:454 ||| NN
was  ||| S:454 E:458 ||| VBD
statistically  ||| S:458 E:472 ||| RB
younger ||| S:472 E:479 ||| JJR
( ||| S:479 E:480 ||| -LRB-
p  ||| S:480 E:481 ||| CD
< ||| S:481 E:482 ||| SYM
0.  ||| S:482 E:485 ||| CD
05 ||| S:485 E:487 ||| CD
) ||| S:487 E:488 ||| -RRB-
than  ||| S:488 E:493 ||| IN
that  ||| S:493 E:498 ||| DT
of  ||| S:498 E:501 ||| IN
the  ||| S:501 E:505 ||| DT
control  ||| S:505 E:513 ||| NN
patients ||| S:513 E:521 ||| NNS
,  ||| S:521 E:523 ||| ,
whereas  ||| S:523 E:531 ||| IN
the  ||| S:531 E:535 ||| DT
duration  ||| S:535 E:544 ||| NN
of  ||| S:544 E:547 ||| IN
home  ||| S:547 E:552 ||| NN
care  ||| S:552 E:557 ||| NN
and  ||| S:557 E:561 ||| CC
home  ||| S:561 E:566 ||| NN
death  ||| S:566 E:572 ||| NN
ratio  ||| S:572 E:578 ||| NN
did  ||| S:578 E:582 ||| VBD
not  ||| S:582 E:586 ||| RB
show  ||| S:586 E:591 ||| VB
significant  ||| S:591 E:603 ||| JJ
differences ||| S:603 E:614 ||| NNS
.  ||| S:614 E:616 ||| .
As  ||| S:616 E:619 ||| RB
for  ||| S:619 E:623 ||| IN
medical  ||| S:623 E:631 ||| JJ
treatment ||| S:631 E:640 ||| NN
,  ||| S:640 E:642 ||| ,
the  ||| S:642 E:646 ||| DT
frequency  ||| S:646 E:656 ||| NN
of  ||| S:656 E:659 ||| IN
the  ||| S:659 E:663 ||| DT
management  ||| S:663 E:674 ||| NN
of  ||| S:674 E:677 ||| IN
nephrostomy  ||| S:677 E:689 ||| NN
was  ||| S:689 E:693 ||| VBD
significantly  ||| S:693 E:707 ||| RB
higher  ||| S:707 E:714 ||| JJR
in  ||| S:714 E:717 ||| IN
cases  ||| S:717 E:723 ||| NNS
with  ||| S:723 E:728 ||| IN
gynecological  ||| S:728 E:742 ||| JJ
malignancies ||| S:742 E:754 ||| NN
.  ||| S:754 E:756 ||| .
However ||| S:756 E:763 ||| RB
,  ||| S:763 E:765 ||| ,
the  ||| S:765 E:769 ||| DT
frequencies  ||| S:769 E:781 ||| NN
of  ||| S:781 E:784 ||| IN
the  ||| S:784 E:788 ||| DT
usage  ||| S:788 E:794 ||| NN
of  ||| S:794 E:797 ||| IN
strong  ||| S:797 E:804 ||| JJ
opioids ||| S:804 E:811 ||| NN
,  ||| S:811 E:813 ||| ,
home  ||| S:813 E:818 ||| NN
oxygen  ||| S:818 E:825 ||| NN
therapy ||| S:825 E:832 ||| NN
,  ||| S:832 E:834 ||| ,
home  ||| S:834 E:839 ||| RB
parenteral  ||| S:839 E:850 ||| JJ
hyperalimentation ||| S:850 E:867 ||| NN
,  ||| S:867 E:869 ||| ,
management  ||| S:869 E:880 ||| NN
of  ||| S:880 E:883 ||| IN
central  ||| S:883 E:891 ||| JJ
venous  ||| S:891 E:898 ||| JJ
port  ||| S:898 E:903 ||| NN
and  ||| S:903 E:907 ||| CC
indwelling  ||| S:907 E:918 ||| JJ
bladder  ||| S:918 E:926 ||| NN
catheter  ||| S:926 E:935 ||| NN
showed  ||| S:935 E:942 ||| VBD
no  ||| S:942 E:945 ||| DT
significant  ||| S:945 E:957 ||| JJ
differences ||| S:957 E:968 ||| NNS
.  ||| S:968 E:970 ||| .
There  ||| S:970 E:976 ||| EX
were  ||| S:976 E:981 ||| VBD
patients ||| S:981 E:989 ||| NNS
,  ||| S:989 E:991 ||| ,
who  ||| S:991 E:995 ||| WP
needed  ||| S:995 E:1002 ||| VBD
special  ||| S:1002 E:1010 ||| JJ
treatments  ||| S:1010 E:1021 ||| NNS
by  ||| S:1021 E:1024 ||| IN
a  ||| S:1024 E:1026 ||| DT
gynecologist ||| S:1026 E:1038 ||| NN
,  ||| S:1038 E:1040 ||| ,
with  ||| S:1040 E:1045 ||| IN
vesicovaginorectal  ||| S:1045 E:1064 ||| JJ
fistula  ||| S:1064 E:1072 ||| NN
in  ||| S:1072 E:1075 ||| IN
one  ||| S:1075 E:1079 ||| CD
case ||| S:1079 E:1083 ||| NN
,  ||| S:1083 E:1085 ||| ,
subcutaneous  ||| S:1085 E:1098 ||| JJ
abscess  ||| S:1098 E:1106 ||| NNS
probably  ||| S:1106 E:1115 ||| RB
caused  ||| S:1115 E:1122 ||| VBN
by  ||| S:1122 E:1125 ||| IN
rectocutaneous  ||| S:1125 E:1140 ||| JJ
fistula  ||| S:1140 E:1148 ||| NN
in  ||| S:1148 E:1151 ||| IN
one  ||| S:1151 E:1155 ||| CD
case ||| S:1155 E:1159 ||| NN
,  ||| S:1159 E:1161 ||| ,
vaginal  ||| S:1161 E:1169 ||| JJ
bleeding  ||| S:1169 E:1178 ||| NN
in  ||| S:1178 E:1181 ||| IN
one  ||| S:1181 E:1185 ||| CD
case  ||| S:1185 E:1190 ||| NN
and  ||| S:1190 E:1194 ||| CC
acute  ||| S:1194 E:1200 ||| JJ
urinary  ||| S:1200 E:1208 ||| NNS
retention  ||| S:1208 E:1218 ||| VBP
treated  ||| S:1218 E:1226 ||| VBN
by  ||| S:1226 E:1229 ||| IN
an  ||| S:1229 E:1232 ||| DT
emergent  ||| S:1232 E:1241 ||| JJ
bladder  ||| S:1241 E:1249 ||| NN
puncture ||| S:1249 E:1257 ||| NN
.  ||| S:1257 E:1259 ||| .
By  ||| S:1259 E:1262 ||| IN
analyzing  ||| S:1262 E:1272 ||| VBG
the  ||| S:1272 E:1276 ||| DT
focus  ||| S:1276 E:1282 ||| NN
problem  ||| S:1282 E:1290 ||| NN
lists  ||| S:1290 E:1296 ||| NNS
of  ||| S:1296 E:1299 ||| IN
the  ||| S:1299 E:1303 ||| DT
total  ||| S:1303 E:1309 ||| JJ
suffering  ||| S:1309 E:1319 ||| NN
at  ||| S:1319 E:1322 ||| IN
each  ||| S:1322 E:1327 ||| DT
clinical  ||| S:1327 E:1336 ||| JJ
phase ||| S:1336 E:1341 ||| NN
,  ||| S:1341 E:1343 ||| ,
in  ||| S:1343 E:1346 ||| IN
patients  ||| S:1346 E:1355 ||| NNS
living  ||| S:1355 E:1362 ||| VBG
longer  ||| S:1362 E:1369 ||| JJR
than  ||| S:1369 E:1374 ||| IN
15  ||| S:1374 E:1377 ||| CD
days  ||| S:1377 E:1382 ||| NNS
at  ||| S:1382 E:1385 ||| IN
home ||| S:1385 E:1389 ||| NN
, ||| S:1389 E:1390 ||| ,
( ||| S:1390 E:1391 ||| -LRB-
Kawagoe ||| S:1391 E:1398 ||| NNP
's  ||| S:1398 E:1401 ||| POS
classification  ||| S:1401 E:1416 ||| NN
in  ||| S:1416 E:1419 ||| IN
1991 ||| S:1419 E:1423 ||| CD
) ||| S:1423 E:1424 ||| -RRB-
this  ||| S:1424 E:1429 ||| DT
did  ||| S:1429 E:1433 ||| VBD
not  ||| S:1433 E:1437 ||| RB
show  ||| S:1437 E:1442 ||| VB
significant  ||| S:1442 E:1454 ||| JJ
difference  ||| S:1454 E:1465 ||| NN
against  ||| S:1465 E:1473 ||| IN
the  ||| S:1473 E:1477 ||| DT
control  ||| S:1477 E:1485 ||| NN
group ||| S:1485 E:1490 ||| NN
.  ||| S:1490 E:1492 ||| .
In  ||| S:1492 E:1495 ||| IN
conclusion ||| S:1495 E:1505 ||| NN
,  ||| S:1505 E:1507 ||| ,
gynecologic  ||| S:1507 E:1519 ||| JJ
cancer  ||| S:1519 E:1526 ||| NN
patients  ||| S:1526 E:1535 ||| NNS
were  ||| S:1535 E:1540 ||| VBD
significantly  ||| S:1540 E:1554 ||| RB
younger  ||| S:1554 E:1562 ||| JJR
than  ||| S:1562 E:1567 ||| IN
those  ||| S:1567 E:1573 ||| DT
with  ||| S:1573 E:1578 ||| IN
non-gynecologic  ||| S:1578 E:1594 ||| JJ
malignancies ||| S:1594 E:1606 ||| NN
,  ||| S:1606 E:1608 ||| ,
though  ||| S:1608 E:1615 ||| RB
not  ||| S:1615 E:1619 ||| RB
statistically  ||| S:1619 E:1633 ||| RB
significant ||| S:1633 E:1644 ||| JJ
,  ||| S:1644 E:1646 ||| ,
showing  ||| S:1646 E:1654 ||| VBG
the  ||| S:1654 E:1658 ||| DT
tendency  ||| S:1658 E:1667 ||| NN
of  ||| S:1667 E:1670 ||| IN
short  ||| S:1670 E:1676 ||| JJ
duration ||| S:1676 E:1684 ||| NN
.  ||| S:1684 E:1686 ||| .
Thus ||| S:1686 E:1690 ||| RB
,  ||| S:1690 E:1692 ||| ,
in  ||| S:1692 E:1695 ||| IN
cases  ||| S:1695 E:1701 ||| NNS
of  ||| S:1701 E:1704 ||| IN
gynecologic  ||| S:1704 E:1716 ||| JJ
malignancies ||| S:1716 E:1728 ||| NN
,  ||| S:1728 E:1730 ||| ,
it  ||| S:1730 E:1733 ||| PRP
is  ||| S:1733 E:1736 ||| VBZ
important  ||| S:1736 E:1746 ||| JJ
to  ||| S:1746 E:1749 ||| TO
take  ||| S:1749 E:1754 ||| VB
these  ||| S:1754 E:1760 ||| DT
characteristics  ||| S:1760 E:1776 ||| NN
into  ||| S:1776 E:1781 ||| IN
consideration ||| S:1781 E:1794 ||| NN
.  ||| S:1794 E:1796 ||| .
